Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
Konstantin HuhnAntonios BayasSebastian DoerckBenedikt FrankKathrin GerbershagenKerstin HellwigBoris KallmannChristoph KleinschnitzIngo KleiterDe-Hyung LeeVolker LimmrothMathias MäurerSven MeuthPeter RieckmannTobias RuckRalf GoldRalf A LinkerPublished in: Journal of neurology (2018)
Therapy switch was highly effective in reducing clinical and MRI surrogates of disease activity and was mainly well tolerated within one year of follow-up. Hence, alemtuzumab constitutes a promising therapy in RRMS with refractory disease activity despite fingolimod treatment. Further studies are warranted to confirm these beneficial findings and to reveal safety concerns in the longer-term follow-up.
Keyphrases
- disease activity
- multiple sclerosis
- rheumatoid arthritis
- systemic lupus erythematosus
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- magnetic resonance imaging
- preterm infants
- mass spectrometry
- dna methylation
- magnetic resonance
- contrast enhanced
- combination therapy
- diffusion weighted imaging
- smoking cessation
- replacement therapy